A Canadian real-world, multi-center, prospective, observational study assessing the treatment duration, the treatment sequence, and the overall survival for patients treated with endocrine therapy ± targeted therapy in HR + HER2-negative advanced bre
Results support current treatment recommendations of early introduction of CDK4/6i in HR + /HER2- aBC.
Authors
- Stéphanie Guillemette
- Ana Elisa Lohmann (ORCID: https://orcid.org/0000-0003-0669-2389)
- Nathaniel Bouganim (ORCID: https://orcid.org/0000-0003-0811-876X)
- Francois Thireau
- Mihaela Mates (ORCID: https://orcid.org/0000-0002-7183-6003)
- Jan‐Willem Henning (ORCID: https://orcid.org/0009-0001-5768-6379)
- Andrés Machado (ORCID: https://orcid.org/0000-0001-7306-8100)
- Nadia Califaretti (ORCID: https://orcid.org/0009-0009-1354-3390)
- Stephen Chia (ORCID: https://orcid.org/0000-0001-7070-4386)
- Catherine Doyle (ORCID: https://orcid.org/0000-0003-4347-919X)
- Swati Kulkarni (ORCID: https://orcid.org/0000-0002-4213-0933)
- John Hilton (ORCID: https://orcid.org/0000-0002-6280-8633)
- Nayyer Iqbal
- Marc‐André Caron
- Ricardo Leite
- Cristiano Ferrario
Institutions
- Western University (CA)
- BC Cancer Agency (CA)
- Grand River Hospital (CA)
- Ottawa Hospital (CA)
- McGill University Health Centre (CA)
- Jewish General Hospital (CA)
- Saskatchewan Cancer Agency (CA)
- Windsor Regional Hospital (CA)
- Centre hospitalier universitaire de Québec (CA)
- Translational Research in Oncology (FR)
- Ottawa Regional Cancer Foundation (CA)
- Kingston Health Sciences Centre (CA)
- Novartis (Canada) (CA)
Publication Details
- Journal
- Breast Cancer Research and Treatment
- Published
- 2025-01-22
- DOI
- https://doi.org/10.1007/s10549-024-07580-8
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Novartis Pharmaceuticals Canada